Newsfeeds - Spark Newswire

2 minute read

Arrowhead Pharma Reports Filing Of Regulatory Clearance To Initiate Phase 1/2a Study Of ARO-MUC5AC For Treatment Of Muco-Obstructive Lung Diseases

March 24, 7:32 AM

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MUC5AC, the company’s investigational RNA interference

ARWR

2 minute read

Arrowhead Completes Enrollment In Phase 2b ARCHES-2 Study Of Investigational ARO-ANG3 For Patients With Mixed Dyslipidemia

By Benzinga Newsdesk

February 24, 8:32 AM

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3, the company's

ARWR

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

February 23, 1:36 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABBV

30 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

February 22, 2:19 PM

During Tuesday's trading, 505 companies set new 52-week lows.

ACRX

2 minute read

Arrowhead Pharma Reports Initiation Of Phase 1/2 Study Of ARO-C3 For Treatment Of Complement Mediated Diseases

By Benzinga Newsdesk

February 18, 8:31 AM

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi)

ARWR

3 minute read

Arrorhead Pharma Reports Will Present Clinical Data On AROHIF21001 At American Society of Clinical Oncology Genitourinary Cancers Symposium Feb. 17-19

By Benzinga Newsdesk

February 17, 8:31 AM

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi)

ARWR

2 minute read

Earnings

Arrowhead Pharmaceuticals’s Return On Capital Employed Insights

By Benzinga Insights

February 3, 10:59 AM

According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of $62.87 million.

ARWR

1 minute read

SVB Leerink Maintains Market Perform on Arrowhead Pharmaceuticals, Lowers Price Target to $36

By Benzinga Newsdesk

February 3, 6:02 AM

SVB Leerink analyst Mani Foroohar maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Market Perform and lowers the price target from $46 to $36.

ARWR

1 minute read

Recap: Arrowhead Pharmaceuticals Q1 Earnings

By Benzinga Insights

February 3, 4:44 AM

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

ARWR

3 minute read

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales

By Shanthi Rexaline

February 2, 8:33 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ABBV